Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluar la eficacia y la seguridad de las cápsulas LivPhcD en sujetos con NAFLD

29 de septiembre de 2026 actualizado por: TCM Biotech International Corp.

Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de las cápsulas LivPhcD en sujetos con NAFLD

Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.

There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.

LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

110

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Not Required For This Country
      • Taipei, Not Required For This Country, Taiwán, 221
        • National Taiwan University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female between 20 and 75 years of age.
  2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
  3. Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
  4. CAP ≥ 238 db/m
  5. Fibro scan (transient elastography) F0~F3

Exclusion Criteria:

  1. Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
  2. Type 1 diabetes mellitus.
  3. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
  4. Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
  5. Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
  6. Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
  7. Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
  8. Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
  9. Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
  10. Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
  11. Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
  12. History of HIV

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Placebo without active ingredient

Placebo matching LivPhcD cap.

Comparador activo: 2 cap.LivPhcD/per day

515mg/LivPhcD cap. 2 cap./per day

2 caps. LivPhcD cap. after meal, once a day

Comparador activo: 4 cap.LivPhcD/per day

515mg/LivPhcD cap. 4 cap./per day, BID

4 caps. LivPhcD cap. after meal, BID

Comparador activo: 6 cap.LivPhcD/per day

515mg/LivPhcD cap. 6 cap./per day, TID

6 caps. LivPhcD cap. after meal, TID

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reduction of Liver Fat
Periodo de tiempo: 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter)

36 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in liver fat at least 30% reduction
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat at least 1 stage reduction
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change of liver fat by CAP

24 weeks and 36 weeks
Stable in liver fat
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fibrosis at least 10% reduction
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis at least 1 stage reduction
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Stable in liver fibrosis
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change of FIB-4

24 weeks and 36 weeks
Change in ALT
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of ALT

24 weeks and 36 weeks
Change in AST
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AST

24 weeks and 36 weeks
Change in GGT
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of GGT

24 weeks and 36 weeks
Change in AP
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AP

24 weeks and 36 weeks
Change in Bilirubin
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Bilirubin

24 weeks and 36 weeks
Change in Triglyceride
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Triglyceride

24 weeks and 36 weeks
Change in Total Cholesterol
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Total Cholesterol

24 weeks and 36 weeks
Change in HDL-C
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of HDL-C

24 weeks and 36 weeks
Change in LDL-C
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of LDL-C

24 weeks and 36 weeks
Change in TNF-α
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of TNF-α

24 weeks and 36 weeks
Change in C-Reactive Protein
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of C-Reactive Protein

24 weeks and 36 weeks
Change in Albumin
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Albumin

24 weeks and 36 weeks
Occurrence of adverse events and serious adverse events
Periodo de tiempo: 24 weeks and 36 weeks

Between group difference in the occurrence of adverse events and serious adverse events.

24 weeks and 36 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de diciembre de 2023

Finalización primaria (Actual)

22 de diciembre de 2025

Finalización del estudio (Actual)

22 de enero de 2026

Fechas de registro del estudio

Enviado por primera vez

28 de mayo de 2023

Primero enviado que cumplió con los criterios de control de calidad

25 de junio de 2023

Publicado por primera vez (Actual)

5 de julio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • LivPhcD-001

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir